LUNG Live signals | Maximize Profits with Getagraph.com

SELL 101943 min ago

@ $14.55

Issued: 14 Feb 2024 @ 09:30

Return: -48.32%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 2.50 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	198 804
Average Volume	573 001
Market Cap	289.80M
EPS	$0 ( 2024-02-21 )
Next earnings date	( $-0.430 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.70
ATR14	$0.00500 (0.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Rose Geoffrey Beran	Sell	1 184	Common Stock
2024-04-03	Joshi Mehul	Buy	0
2024-03-22	Rose Geoffrey Beran	Sell	1 184	Common Stock
2024-03-15	Williamson Steven S.	Buy	425 116	Employee Stock Option (right to buy)
2024-03-15	Williamson Steven S.	Buy	205 286	Common Stock

INSIDER POWER
77.49
Last 98 transactions
Buy: 1 710 475 \| Sell: 224 988

Volume Correlation

Long: -0.19 (neutral)

Short: 0.54 (weak)

Signal:(46.477) Neutral

Pulmonx Corporation Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pulmonx Corporation Correlation - Currency/Commodity

0.78
( moderate )

0.58
( weak )

0.00
( neutral )

0.70
( moderate )

0.37
( neutral )

-0.72
( moderate negative )

Pulmonx Corporation Financials

Annual	2023
Revenue:	$68.68M
Gross Profit:	$50.35M (73.32 %)
EPS:	$-1.600

Q4	2023
Revenue:	$19.28M
Gross Profit:	$14.30M (74.18 %)
EPS:	$-0.360

Q3	2023
Revenue:	$17.67M
Gross Profit:	$13.03M (73.74 %)
EPS:	$-0.390

Q2	2023
Revenue:	$17.19M
Gross Profit:	$12.73M (74.06 %)
EPS:	$-0.430

Financial Reports:

No articles found.

Pulmonx Corporation

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.